(352) Ionic liquid-based nanoemulsion to improve sorafenib oral absorption & repurposing it in AML therapy

Introduction: Acute myeloid leukemia (AML) is a hematological malignancy with FLT3 mutations being the most common, driving aggressive progression [1]. Sorafenib (SRF), an FDA-approved drug repurposed for AML with FLT3 mutations faces challenges due to poor solubility & low oral bioavailability (38-49%) [2, 3]. Ionic liquids (ILs) offer excellent solvation properties. Previously we developed metformin-docusate (MD), an amphiphilic IL with high lipid solubility [4]. Here, we created a self-nanoemulsifying system (SNES) of MD with solubilized SRF to improve its bioavailability & therapeutic potential for AML.